GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Plus Therapeutics Inc (NAS:PSTV) » Definitions » FCF Yield %

Plus Therapeutics (Plus Therapeutics) FCF Yield % : -166.00 (As of May. 03, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Plus Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Plus Therapeutics's Trailing 12-Month Free Cash Flow is $-13.01 Mil, and Market Cap is $7.84 Mil. Therefore, Plus Therapeutics's FCF Yield % for today is -166.00%.

The historical rank and industry rank for Plus Therapeutics's FCF Yield % or its related term are showing as below:

PSTV' s FCF Yield % Range Over the Past 10 Years
Min: -1781.64   Med: -81.41   Max: -10.05
Current: -166


During the past 13 years, the highest FCF Yield % of Plus Therapeutics was -10.05%. The lowest was -1781.64%. And the median was -81.41%.

PSTV's FCF Yield % is ranked worse than
90.35% of 1555 companies
in the Biotechnology industry
Industry Median: -14.42 vs PSTV: -166.00

Plus Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.


Plus Therapeutics FCF Yield % Historical Data

The historical data trend for Plus Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Plus Therapeutics FCF Yield % Chart

Plus Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -64.13 -65.48 -64.01 -128.91 -167.29

Plus Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -84.31 -224.90 -191.79 -159.00 -98.90

Competitive Comparison of Plus Therapeutics's FCF Yield %

For the Biotechnology subindustry, Plus Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Plus Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Plus Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Plus Therapeutics's FCF Yield % falls into.



Plus Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Plus Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-13.011 / 7.77761941
=-167.29%

Plus Therapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-1.923 * 4 / 7.77761941
=-98.90%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Plus Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Plus Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Plus Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Plus Therapeutics (Plus Therapeutics) Business Description

Traded in Other Exchanges
Address
4200 Marathon Boulevard, Suite 200, Austin, TX, USA, 78756
Plus Therapeutics Inc is a clinical-stage pharmaceutical company. The company focused on the discovery, development, and delivery of complex and innovative treatments for patients battling cancer and rare diseases. Its product pipeline includes Patented RNL and Patented DocePLUS.
Executives
Marc H Hedrick officer: President C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
Robert P Lenk director LUNA INNOVATIONS INCORPORATED, 2851 COMMERCE STREET, BLACKSBURG VA 24060
Howard Clowes director 217 DWIGHT ROAD, BURLINGAME CA 94010
Greg Petersen director 3100 MAIN STREET, SUITE 900, HOUSTON TX 77002
Sims Andrew John Hugh Macintyre officer: Chief Financial Officer 4200 MARATHON BOULEVARD, SUITE 200, AUSTIN TX 78756
Norman D. Lafrance officer: CHIEF MEDICAL OFFICER MOLECULAR INSIGHT PHARMCEUTICALS, INC., 160 SECOND STREET, CAMBRIDGE MA 02142
Es-johansson An Van director 6863 BEE CAVE ROAD, SUITE 200, AUSTIN TX 78736
Ag Postfinance 10 percent owner MINGERSTRASSE 20, BERN V8 3030
Bank Sa Swissquote 10 percent owner CHEMIN DE LA CRETAUX 33, GLAND V8 1196
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Ron Martell director PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Mark Marino officer: Chief Medical Officer C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
John David Harris officer: VP and GM of Cell Therapy 3020 CALLAN ROAD, SAN DIEGO CA 92121
Gail K Naughton director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
David Rickey director